RUNX1 restrains STAT1-GITRL signaling to shape an immunosuppressive CRC microenvironment.

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• The role of RUNX1 in epithelial tumors is recognized, but its function in the colorectal cancer (CRC) tumor immune microenvironment (TME) is unclear.
• Understanding RUNX1's impact on TME is crucial for developing effective CRC therapies.

Purpose of the Study:

• To investigate RUNX1's contribution to TME remodeling in colorectal cancer.
• To elucidate the molecular mechanisms by which RUNX1 influences immune cell infiltration and function in CRC.

Main Methods:

• Analysis of clinical CRC tissues to correlate RUNX1 expression with immune cell infiltration and GITRL levels.
• In vitro and in vivo functional studies using mouse models to assess the impact of RUNX1 on immune responses and therapeutic sensitivity.
• Mechanistic studies involving protein-protein interactions and transcriptional regulation.

Main Results:

• RUNX1 expression negatively correlates with GITRL levels and is associated with increased Treg cell infiltration in CRC.
• RUNX1 impairs GITRL-GITR signaling, promoting Treg infiltration and suppressing CD8+ T cell activation.
• Elevated RUNX1 enhances CRC tumor sensitivity to GITR agonistic antibody therapy.
• RUNX1 interacts with STAT1 to inhibit GITRL transcription.

Conclusions:

• The RUNX1/STAT1/GITRL axis plays a significant role in CRC immune evasion.
• Targeting this axis offers a potential therapeutic strategy for enhancing GITR-based immunotherapy in colorectal cancer.